Does Selank Help with Anxiety?
Current research suggests that Selank may support the regulation of anxiety and stress resistance. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic peptide derived from the naturally occurring immunological peptide tuftsin. It was developed in Russia for research into anxiety disorders, stress responses, and emotional regulation [1–5].
Unlike traditional anxiolytics, which primarily act via benzodiazepine receptors, Selank appears to affect several biological systems simultaneously. Research indicates that it may interact with GABA signalling, endogenous opioid peptides called enkephalins, neurotrophic factors, and immunological pathways associated with stress response and emotional balance [1–4]. More and more people are looking for information about Selank for anxiety, as research suggests that this peptide may influence mechanisms related to the stress response, emotional regulation, and the functioning of the nervous system.
Due to its broad spectrum of action, Selank is of great interest as a peptide being studied for conditions associated with anxiety and chronic stress.
Research on Selank in the Context of Anxiety
Several studies have focused directly on the potential anxiolytic effects of Selank.
One of the first mechanistic studies demonstrated that Selank inhibits enzymes responsible for the breakdown of enkephalins. These naturally occurring neuropeptides play a significant role in mood regulation, stress adaptation, and emotional processing. Researchers suggested that preserving enkephalin activity may contribute to Selank's anxiolytic effects, as disturbances in enkephalin metabolism have been observed in individuals with generalised anxiety disorder (GAD) [2].
Further laboratory research has shown that Selank acts as a positive allosteric modulator of GABA receptors. Instead of directly activating GABA receptors, as benzodiazepines do, Selank influences GABA signalling in a more indirect way. This mechanism may explain its anxiolytic effects while limiting the sedation often seen with traditional anti-anxiety medications [1].
Similar results were obtained in animal studies. Long-term administration of the peptide TP-7, an analogue of Selank, significantly reduced anxiety-related behaviours in rats throughout the entire four-week study period, without affecting body weight or general activity of the animals [6].
Selank for Anxiety in Human Studies
Clinical trials on Selank have primarily been conducted in Russia, particularly in patients with generalised anxiety disorder (GAD) and neurasthenia.
In a randomised clinical trial involving 62 patients, researchers directly compared Selank with medazepam, a benzodiazepine drug. Both therapies led to a comparable reduction in anxiety symptoms. At the same time, Selank demonstrated an anti-asthenic effect and a mild psychostimulating effect, suggesting the possibility of reducing anxiety while maintaining alertness and mental acuity instead of causing drowsiness [3].
Scientists also observed an improvement in markers related to enkephalin activity during therapy, which further supports the proposed mechanism of action for Selank [3].
These results are particularly interesting because many classic anti-anxiety drugs can cause drowsiness, cognitive impairment, the development of tolerance, or withdrawal symptoms. The available data suggest that Selank acts via different neurochemical pathways.
Is Selank effective for anxiety?
Current scientific evidence suggests that Selank may have beneficial effects on anxiety symptoms, particularly those associated with chronic stress and generalised anxiety disorder.
Both animal and clinical studies have consistently demonstrated anxiolytic effects, and mechanistic studies have identified several biological pathways that may be responsible for the observed effects [1–6].
Research suggests that Selank may affect anxiety through:
- modulation of GABA receptor activity,
- inhibition of enkephalin degradation,
- regulation of brain-derived neurotrophic factor (BDNF),
- impact on neurotransmitter systems involved in emotion regulation,
- modulation of the immune response and inflammatory pathways [1,2,4,5].
Although these results are promising, most clinical trials have been relatively small and larger, modern trials are needed to better define long-term efficacy and safety.
What sensations can Selank cause?
Scientific research does not directly measure subjective feelings like „how Selank works,” however, published results offer some clues.
In clinical trials, a reduction in anxiety symptoms, decreased mental fatigue, lowered emotional tension, and improved overall functioning were observed [3]. Animal studies have also shown a reduction in anxiety-related behaviours without apparent sedative effects [6].
For this reason, Selank is often described in scientific literature as a peptide that provides a calming and anxiolytic effect while maintaining mental performance and alertness. This profile differs from many classic anxiolytic drugs, which often induce significant sedation [1–3].
Does Selank work similarly to Diazepam?
Current data suggest that Selank and diazepam reduce anxiety through entirely different mechanisms.
Diazepam works by directly binding to benzodiazepine sites on GABA-A receptors, producing anxiolytic, sedative, muscle relaxant and anticonvulsant effects. Sedation is a typical effect of this mechanism.
Selank, on the other hand, appears to indirectly influence GABA signalling, and additionally acts on enkephalins, neurotrophic factors, and immunological pathways [1,2]. Experimental studies suggest it may retain anxiolytic effects while limiting some of the sedative actions typical of benzodiazepines [4].
Although both compounds exhibit anxiolytic properties, available evidence indicates that Selank is not a counterpart to diazepam and possesses a different pharmacological profile.
Does Selank work like a benzodiazepine?
Research suggests that Selank should not be classified as a traditional benzodiazepine.
In animal studies, Selank has been shown to enhance the anxiolytic effects of certain benzodiazepines while reducing their sedative and muscle-relaxant effects. Researchers also observed that Selank counteracted the reduction in motor activity induced by diazepam and olanzapine, further highlighting its distinct mechanism of action [4].
Furthermore, molecular studies suggest that Selank influences the GABAergic system in a different way than direct activation of benzodiazepine receptors [1].
For this reason, Selank is usually classified as an anxiolytic peptide with a unique biological profile, rather than as a benzodiazepine-like substance.
Summary
Current research suggests that Selank may support anxiety reduction, stress resilience, and emotional regulation by interacting with multiple biological pathways. Study results indicate that it may affect GABA signalling, protect endogenous enkephalins from degradation, regulate neurotrophic factors, and interact with immunological mechanisms related to stress response.
Clinical trials involving humans have demonstrated an anxiolytic effect comparable to some conventional medications, while maintaining alertness and cognitive function. However, it should be noted that a significant portion of the available research originates from Russia and Eastern Europe, and further international clinical studies are needed to fully assess the efficacy, safety, and long-term effects of Selank.
Disclaimer
This article is for educational and informational purposes only. Selank is a research peptide, and scientific knowledge regarding its mechanisms of action and long-term effects is constantly evolving. The information presented is a summary of findings from clinical, preclinical, and laboratory studies, and should not be interpreted as medical advice, a therapeutic recommendation, or a confirmation of efficacy.
For research purposes only: Selank products supplied by Semax Polska are intended solely for laboratory and scientific research. They are not authorised for human consumption or for use for medical, diagnostic, therapeutic or prophylactic purposes. All research materials should be used in accordance with applicable legislation and laboratory testing standards.
References
[1] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[3] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalised Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[4] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined Action of Benzodiazepine Tranquillisers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[5] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[6] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on Anxiety-Phobic States and Body Weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804.